IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2025 | $19.00 | Buy | Chardan Capital Markets |
| 11/3/2025 | $20.00 | Mkt Outperform | Citizens JMP |
| 9/3/2025 | $23.00 | Strong Buy | Raymond James |
| 7/23/2025 | $3.00 | Neutral | Piper Sandler |
| 5/7/2025 | $20.00 | Outperform | Leerink Partners |
| 4/8/2025 | Outperform | William Blair |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Chardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00
Citizens JMP initiated coverage of Kalaris Therapeutics with a rating of Mkt Outperform and set a new price target of $20.00
Raymond James initiated coverage of Kalaris Therapeutics with a rating of Strong Buy and set a new price target of $23.00
Piper Sandler resumed coverage of Kalaris Therapeutics with a rating of Neutral and set a new price target of $3.00
Leerink Partners initiated coverage of Kalaris Therapeutics with a rating of Outperform and set a new price target of $20.00
William Blair initiated coverage of Kalaris Therapeutics with a rating of Outperform
Fastest customizable press release news feed in the world
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses. The private placement includes participation from both new and existing investors, including ADAR1 Capital Management, Coastlands Capital, Invus
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time: 3:20 – 3:50pm ETLocation: Lotte New York Palace Hotel, New York, NY Kalaris management will be available for one-on-one meetings during the conference. Interested parties should cont
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Details: Type: Company PresentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, June 5th, 2025Time: 03:00 pm ETLocation: Webcast Follow
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLocation: Webcast Following the event, a replay will be hosted on Kalaris Therapeutics' Investor Relations webpage. About Kalaris Kalaris is a clinical-stage
SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
DEFA14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
3 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
Live finance-specific insights
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 Kalaris conference call today at 4:30 pm EST BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical c